Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.75 |
| ▸ | DRD3 | P35462 | 4/20 | 0.75 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.62 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.61 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | HTR1A | P08908 | 2/20 | 0.56 |
| ▸ | DRD4 | P21917 | 2/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.55 |
| ▸ | RAD52 | P43351 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.51 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28396664 | 0.89 | ADRB1 (0.71) | DRD2DRD3ADRB1KDM4ELMNA | |
| SCHEMBL3399254 | 0.86 | DRD2 (1.00) | DRD2DRD3ADRA2CBCL2A1ADRB1 | |
| SCHEMBL12359055 | 0.84 | DRD2 (0.71) | DRD2DRD3ADRA2CBCL2A1KDM4E | |
| SCHEMBL6002186 | 0.83 | DRD2 (0.69) | DRD2DRD3ADRA2CBCL2A1KDM4E | |
| SCHEMBL25106971 | 0.80 | DRD2 (0.65) | DRD2DRD3ADRA2CBCL2A1KDM4E | |
| SCHEMBL3399574 | 0.80 | DRD2 (0.87) | DRD2DRD3ADRA2CBCL2A1ADRB1 | |
| SCHEMBL30407939 | 0.79 | ADRB1 (0.65) | DRD2DRD3ADRB1KDM4ELMNA | |
| SCHEMBL1825806 | 0.79 | ADRB1 (0.65) | DRD2DRD3ADRB1KDM4ELMNA | |
| SCHEMBL6002162 | 0.79 | DRD2 (0.54) | DRD2DRD3ADRA2CBCL2A1KDM4E | |
| SCHEMBL22092310 | 0.79 | DRD2 (0.63) | DRD2DRD3ADRA2CBCL2A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5378690-A | Treatment of angiotensin induced hypertension | SANKYO COMPANY, LIMITED (JP) | 1995-01-03 | — | — | US | claimed |
| US-11345711-B2 | 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones | Impact Therapeutics (Shanghai), Inc (CN) | 2022-05-31 | — | — | US | disclosed |
| US-11345710-B2 | Imidazo[1,2-b]pyrimido[4,5-d]pyridazin-5(6H)-ones and the use thereof | Impact Therapeutics (Shanghai), Inc (CN) | 2022-05-31 | — | — | US | disclosed |
| US-20200385394-A1 | 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES | Impact Therapeutics (Shanghai), Inc (CN) | 2020-12-10 | — | — | US | disclosed |
| US-10703759-B2 | 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones | IMPACT THERAPEUTICS, INC (CN) | 2020-07-07 | — | — | US | disclosed |
| US-20200131192-A1 | IMIDAZO[1,2-b]PYRIMIDO[4,5-d]PYRIDAZIN-5(6H)-ONES AND THE USE THEREOF | IMPACT THERAPEUTICS, INC. (CN) | 2020-04-30 | — | — | US | disclosed |
| EP-2930170-B1 | PYRIDONE COMPOUND FOR USE IN THE TREATMENT OF DERMATOLOGICAL DISORDERS | KYOWA KIRIN CO LTD (JP) | 2020-02-05 | — | — | EP | disclosed |
| US-20190308984-A1 | 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES | Impact Therapeutics (Shanghai), Inc (CN) | 2019-10-10 | — | — | US | disclosed |
| WO-2019178510-A1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | KEZAR LIFE SCIENCES (US) | 2019-09-19 | — | — | WO | disclosed |
| US-10208000-B2 | Eis inhibitors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2019-02-19 | — | — | US | disclosed |
| US-20070066586-A1 | ANILINE DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2007-03-22 | — | — | US | disclosed |
| US-20070043060-A1 | OXAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-02-22 | — | — | US | disclosed |
| US-20070043060-A1 | OXAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-02-22 | — | — | US | disclosed |
| WO-2006071730-A1 | PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ASTRAZENECA AB (SE) | 2006-07-06 | — | — | WO | disclosed |
| WO-2003007959-A1 | QUINOXALINE DERIVATIVES WHICH HAVE PARP INHIBITORY ACTION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-01-30 | — | — | WO | disclosed |
| US-6221868-B1 | Remedies/preventives for frequent urination/urinary incontinence and tropone derivatives | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2001-04-24 | — | — | US | disclosed |
| EP-0995741-A1 | REMEDIES/PREVENTIVES FOR FREQUENT URINATION/URINARY INCONTINENCE AND TROPONE DERIVATIVES | Nippon Kayaku Kabushiki Kaisha (JP) | 2000-04-26 | — | — | EP | disclosed |
| US-5789412-A | 5-HYDROXYTRYPTAMINE (SEROTONIN) RECEPTOR ANTAGONISTS FOR THE CURATIVE OR PREVENTIVE TREATMENT OF PAIN, DEPRESSION, OBSESSIVE COMPULSIVE DISORDERS, ANXIETY OR PANIC ATTACK, OR CANCER | PIERRE FABRE MEDICAMENT (FR) | 1998-08-04 | — | — | US | disclosed |
| US-5378690-A | Treatment of angiotensin induced hypertension | SANKYO COMPANY, LIMITED (JP) | 1995-01-03 | — | — | US | disclosed |
| EP-0274259-A2 | New renin-inhibitory oligopeptides, their preparaton and their use | Sankyo Company Limited (JP) | 1988-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131192-A1 | IMIDAZO[1,2-b]PYRIMIDO[4,5-d]PYRIDAZIN-5(6H)-ONES AND THE USE THEREOF | WEE1, WEE2, CCNE1 | DRD2 4402/4885DRD3 4133/4885ADRA2C 2113/4885 |
| US-20070066586-A1 | ANILINE DERIVATIVES | SERPINB1, ACE, REN | DRD2 1943/4885DRD3 1388/4885ADRA2C 642/4885 |
| US-20190308984-A1 | 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES | WEE1, WEE2, CCNE1 | DRD2 4463/4885DRD3 4251/4885ADRA2C 2739/4885 |
| US-11345711-B2 | 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones | WEE1, WEE2, CCNE1 | DRD2 4463/4885DRD3 4251/4885ADRA2C 2739/4885 |
| US-10703759-B2 | 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones | WEE1, WEE2, CCNE1 | DRD2 4463/4885DRD3 4251/4885ADRA2C 2739/4885 |
| US-11345710-B2 | Imidazo[1,2-b]pyrimido[4,5-d]pyridazin-5(6H)-ones and the use thereof | WEE1, WEE2, CCNE1 | DRD2 4402/4885DRD3 4133/4885ADRA2C 2113/4885 |
| US-20070043060-A1 | OXAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | OXA1L, ARG2, CYP3A7 | DRD2 1146/4885DRD3 745/4885ADRA2C 642/4885 |
| US-10208000-B2 | Eis inhibitors | ABCC1, ATP5ME, ABCG2 | DRD2 4510/4885DRD3 4123/4885ADRA2C 1746/4885 |
| US-20200385394-A1 | 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES | WEE1, WEE2, CCNE1 | DRD2 4463/4885DRD3 4251/4885ADRA2C 2739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.